TURBT联合吉西他滨膀胱灌注治疗非肌层浸润性膀胱癌的效果观察OA

Objective:To investigate the clinical value of transurethral resection of bladder tumor(TURBT)combined with gemcitabine intravesical perfusion in patients with non-muscular invasive bladder cancer(NMIBC).Method:Eighty-six NMIBC patients admitted to the Affiliated Cancer Hospital of Guizhou Medical University between April 2018 and April 2022 were selected as the study objects and the clinical data were retrospectively analysed.All cases were treated with TURBT,and the patients were divided into group A and group B according to the variability of the medication regimen,with 43 cases in each group.The patients of group A were treated with gemcitabine intravesical perfusion,the patients of group B were treated with bladder infusion of pirarubicin.Surgery-related conditions,changes in serum tumour markers[carcinoembryonic antigen(CEA),cancer antigen 199(CA199),cytokeratin(CK19)],levels of T-lymphocyte subpopulations,adverse reactions and postoperative tumour recurrence were compared between the two groups.Result:The levels of CEA,CA199,and CK19 in group A were lower than those in group B,and the difference was statistically significant(P>0.05).The levels of CD3+,CD4+,and CD4+/CD8+in group A were higher than those in group B,and the difference was statistically significant(P>0.05).The incidence of bladder irritation signs and gastrointestinal reactions in group A were lower than those in group B,and the difference was statistically significant(P>0.05).There was no significant difference in operation time,hospital stay,catheter indwelling time,intraoperative blood loss,incidence of hematuria and cystitis,and postoperative recurrence between the two groups(P>0.05).Conclusion:In the treatment of NMIBC patients,TURBT combined with gemcitabine bladder perfusion therapy has a good effect,can improve the serum tumour marker levels,and protect the immune function of patients.What's more,there are fewer adverse reactions during the treatment.